Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony W Ho

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divideMichelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
Cephalalgia : an International Journal of Headache|June 20, 2012
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment designTony W Ho, Eric Pearlman, Donald Lewis, et al.
Headache|January 7, 2012
Randomized, controlled study of telcagepant in patients with migraine and coronary artery diseaseTony W Ho, Andrew P Ho, Bernard R Chaitman, et al.
Cephalalgia : an International Journal of Headache|May 1, 2015
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraineTony W Ho, Andrew P Ho, Yang Joy Ge, et al.
Headache|October 20, 2012
Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineursDavid J Hewitt, Eric Pearlman, Mirja Hämäläinen, et al.
Oncotarget|May 20, 2017
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance settingBrian A Dougherty, Zhongwu Lai, Darren R Hodgson, et al.
Nature Communications|January 8, 2025
High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infectionDaniel T Claiborne, Zachary Detwiler, Steffen S Docken, et al.
The CRISPR Journal|December 21, 2020
Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment MethodsHemangi G Chaudhari, Jon Penterman, Holly J Whitton, et al.
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divideMichelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
Cephalalgia : an International Journal of Headache|June 20, 2012
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment designTony W Ho, Eric Pearlman, Donald Lewis, et al.
Headache|January 7, 2012
Randomized, controlled study of telcagepant in patients with migraine and coronary artery diseaseTony W Ho, Andrew P Ho, Bernard R Chaitman, et al.
Cephalalgia : an International Journal of Headache|May 1, 2015
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraineTony W Ho, Andrew P Ho, Yang Joy Ge, et al.
Headache|October 20, 2012
Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineursDavid J Hewitt, Eric Pearlman, Mirja Hämäläinen, et al.
Oncotarget|May 20, 2017
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance settingBrian A Dougherty, Zhongwu Lai, Darren R Hodgson, et al.
Nature Communications|January 8, 2025
High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infectionDaniel T Claiborne, Zachary Detwiler, Steffen S Docken, et al.
The CRISPR Journal|December 21, 2020
Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment MethodsHemangi G Chaudhari, Jon Penterman, Holly J Whitton, et al.
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Pageof 5